[BrightGene Biotech] Announcement of Board of Directors' Approval of First Quarter 2026 Consolidated Financial Report
BrightGene Biotech's Board of Directors approved the consolidated financial report for the first quarter of 2026 (115 ROC year). The company reported operating revenue of NT$84.385 million, profit before tax of NT$27.985 million, net profit of NT$23.944 million, and basic EPS of NT$0.97.
📋 Article Processing Timeline
- 📰 Published: May 12, 2026 at 09:00
- 🔍 Collected: May 13, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 13, 2026 at 10:39 (2h 39m after Collected)
1. Date of submission to or resolution by the Board of Directors: 115/05/12
2. Date of approval by the Audit Committee: 115/05/12
3. Reporting period for financial report or annual self-assessed financial information (Start Date ~ End Date): 115/01/01~115/03/31
4. Cumulative operating revenue from January 1 to this period (in thousands of NT$): 84,385
5. Cumulative gross profit (loss) from January 1 to this period (in thousands of NT$): 64,455
6. Cumulative operating income (loss) from January 1 to this period (in thousands of NT$): 25,464
7. Cumulative profit (loss) before tax from January 1 to this period (in thousands of NT$): 27,985
8. Cumulative net profit (loss) for the period from January 1 to this period (in thousands of NT$): 23,944
9. Cumulative net profit (loss) attributable to owners of the parent from January 1 to this period (in thousands of NT$): 23,944
10. Cumulative basic earnings per share (loss) from January 1 to this period (in NT$): 0.97
11. Total assets at end of period (in thousands of NT$): 726,709
12. Total liabilities at end of period (in thousands of NT$): 98,435
13. Equity attributable to owners of the parent at end of period (in thousands of NT$): 628,274
14. Other matters that should be noted: None.
Keywords: Important Information
*Company Business: (Assumed based on typical press releases of this nature, no specific info provided in original text)* The company likely operates in the biotechnology and pharmaceutical sector, focusing on R&D for new drugs and treatments.
*Official URL: (Not provided in original text)*
*Address: (Not provided in original text)*
*Established: (Not provided in original text)*
*Capital: (Not provided in original text)*
*Employees: (Not provided in original text)*
*CEO: (Not provided in original text)*
*Business Description: (Assumed)* Engaged in the research, development, and commercialization of innovative biopharmaceutical products and therapeutic solutions for unmet medical needs.
*Image Description: (Not applicable, no image provided)*
*Alt JA: (Not applicable)*
*Alt EN: (Not applicable)*
*Alt ZH: (Not applicable)*
2. Date of approval by the Audit Committee: 115/05/12
3. Reporting period for financial report or annual self-assessed financial information (Start Date ~ End Date): 115/01/01~115/03/31
4. Cumulative operating revenue from January 1 to this period (in thousands of NT$): 84,385
5. Cumulative gross profit (loss) from January 1 to this period (in thousands of NT$): 64,455
6. Cumulative operating income (loss) from January 1 to this period (in thousands of NT$): 25,464
7. Cumulative profit (loss) before tax from January 1 to this period (in thousands of NT$): 27,985
8. Cumulative net profit (loss) for the period from January 1 to this period (in thousands of NT$): 23,944
9. Cumulative net profit (loss) attributable to owners of the parent from January 1 to this period (in thousands of NT$): 23,944
10. Cumulative basic earnings per share (loss) from January 1 to this period (in NT$): 0.97
11. Total assets at end of period (in thousands of NT$): 726,709
12. Total liabilities at end of period (in thousands of NT$): 98,435
13. Equity attributable to owners of the parent at end of period (in thousands of NT$): 628,274
14. Other matters that should be noted: None.
Keywords: Important Information
*Company Business: (Assumed based on typical press releases of this nature, no specific info provided in original text)* The company likely operates in the biotechnology and pharmaceutical sector, focusing on R&D for new drugs and treatments.
*Official URL: (Not provided in original text)*
*Address: (Not provided in original text)*
*Established: (Not provided in original text)*
*Capital: (Not provided in original text)*
*Employees: (Not provided in original text)*
*CEO: (Not provided in original text)*
*Business Description: (Assumed)* Engaged in the research, development, and commercialization of innovative biopharmaceutical products and therapeutic solutions for unmet medical needs.
*Image Description: (Not applicable, no image provided)*
*Alt JA: (Not applicable)*
*Alt EN: (Not applicable)*
*Alt ZH: (Not applicable)*